RIL
CYTK icon

Rothschild Investment LLC’s Cytokinetics CYTK Stock Holding History

Rothschild Investment LLC’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Buy
215
+10
+5% +$718 ﹤0.01% 1578
2026
Q1 		$13.5K Buy
205
+18
+10% +$1.14K ﹤0.01% 1569
2025
Q4 		$11.9K Buy
187
+2
+1% +$124 ﹤0.01% 1509
2025
Q3 		$10.2K Sell
185
-35
-16% -$1.44K ﹤0.01% 1441
2025
Q2 		$7.27K Buy
220
+60
+38% +$2.09K ﹤0.01% 1342
2025
Q1 		$6.43K Buy
160
+55
+52% +$2.53K ﹤0.01% 1326
2024
Q4 		$4.94K Buy
105
+10
+11% +$519 ﹤0.01% 1347
2024
Q3 		$5.02K Buy
95
+80
+533% +$4.46K ﹤0.01% 1291
2024
Q2 		$813 Buy
15
+5
+50% +$302 ﹤0.01% 1769
2024
Q1 		$701 Buy
+10
New +$773 ﹤0.01% 1295

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rothschild Investment LLC's CYTK Position: Q2 2026 in Review

Rothschild Investment LLC increased its Cytokinetics (CYTK) stake by 4.9% in Q2 2026, buying an estimated $718 and bringing the position to 215 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1578.

Rothschild Investment LLC first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Rothschild Investment LLC held 215 shares of Cytokinetics worth $18.3K as of Q2 2026.
  • Rothschild Investment LLC bought 10 Cytokinetics shares in Q2 2026, an estimated $718.
  • Cytokinetics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1578 holding.
  • Rothschild Investment LLC first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.